Follow
Kristopher A. Sarosiek
Kristopher A. Sarosiek
Harvard School of Public Health (Dana-Farber Cancer Institute; Harvard Medical School)
Verified email at hsph.harvard.edu - Homepage
Title
Cited by
Cited by
Year
Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
R Singh, A Letai, K Sarosiek
Nature reviews Molecular cell biology 20 (3), 175-193, 2019
16002019
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy.
TN Chonghaile*, KA Sarosiek*, TT Vo, JA Ryan, A Tammareddi, ...
Science (*equal contribution) 334 (6059), 1129-1133., 2011
6362011
Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy
J Montero, KA Sarosiek, JD DeAngelo, O Maertens, J Ryan, D Ercan, ...
Cell 160 (5), 977-989, 2015
3782015
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
JA Burger, DA Landau, A Taylor-Weiner, I Bozic, H Zhang, K Sarosiek, ...
Nature communications 7 (1), 11589, 2016
3772016
Differentiation stage–specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas
R Malumbres, KA Sarosiek, E Cubedo, JW Ruiz, X Jiang, RD Gascoyne, ...
Blood, The Journal of the American Society of Hematology 113 (16), 3754-3764, 2009
3372009
Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma
SK McBrayer, JR Mayers, GJ DiNatale, DD Shi, J Khanal, AA Chakraborty, ...
Cell 175 (1), 101-116. e25, 2018
2932018
BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response
KA Sarosiek, X Chi, JA Bachman, JJ Sims, J Montero, L Patel, A Flanagan, ...
Molecular cell 51 (6), 751-765, 2013
2712013
CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer
SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ...
Cell reports 17 (9), 2367-2381, 2016
2672016
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
N Johnson, SF Johnson, W Yao, YC Li, YE Choi, AJ Bernhardy, Y Wang, ...
Proceedings of the National Academy of Sciences 110 (42), 17041-17046, 2013
2652013
Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics
KA Sarosiek, C Fraser, N Muthalagu, PD Bhola, W Chang, SK McBrayer, ...
Cancer cell 31 (1), 142-156, 2017
2422017
Mitochondria: gatekeepers of response to chemotherapy
KA Sarosiek, TN Chonghaile, A Letai
Trends in cell biology 23 (12), 612-619, 2013
1842013
PTP1B is a negative regulator of interleukin 4–induced STAT6 signaling
X Lu, R Malumbres, B Shields, X Jiang, KA Sarosiek, Y Natkunam, ...
Blood, The Journal of the American Society of Hematology 112 (10), 4098-4108, 2008
1562008
Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH 3 mimetics–recent successes, current challenges and future promise
KA Sarosiek, A Letai
The FEBS journal 283 (19), 3523-3533, 2016
1142016
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas
KA Sarosiek, R Malumbres, H Nechushtan, AJ Gentles, E Avisar, ...
Blood, The Journal of the American Society of Hematology 115 (3), 570-580, 2010
1072010
Apoptotic cell death in disease—Current understanding of the NCCD 2023
I Vitale, F Pietrocola, E Guilbaud, SA Aaronson, JM Abrams, D Adam, ...
Cell Death & Differentiation 30 (5), 1097-1154, 2023
1062023
Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma
KA Sarosiek, LE Cavallin, S Bhatt, NL Toomey, Y Natkunam, W Blasini, ...
Proceedings of the National Academy of Sciences 107 (29), 13069-13074, 2010
1052010
T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6
X Lu, J Chen, RT Sasmono, ED Hsi, KA Sarosiek, T Tiganis, IS Lossos
Molecular and cellular biology 27 (6), 2166-2179, 2007
1012007
Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers
AN Hata, A Yeo, AC Faber, E Lifshits, Z Chen, KA Cheng, Z Walton, ...
Cancer research 74 (11), 3146-3156, 2014
1002014
Radiation-induced cardiovascular toxicity: mechanisms, prevention, and treatment
J Spetz, J Moslehi, K Sarosiek
Current treatment options in cardiovascular medicine 20, 1-11, 2018
912018
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
PS Winter, KA Sarosiek, KH Lin, M Meggendorfer, S Schnittger, A Letai, ...
Science signaling 7 (357), ra122-ra122, 2014
882014
The system can't perform the operation now. Try again later.
Articles 1–20